RTALB.E — RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Market Cap
TRY1.94bn
Enterprise Value
TRY2.01bn
Revenue
TRY158.59m

Annual income statement for RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS, fiscal year end - December 31st, TRY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	230	384	191	139	159
Cost of Revenue
Gross Profit	111	156	65.3	25.9	42.1
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	181	292	153	82.7	197
Operating Profit	49.3	92.7	37.9	55.8	-38.1
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	88	147	173	-105	-51.7
Provision for Income Taxes
Net Income After Taxes	78.4	127	136	-103	52.2
Minority Interest
Net Income Before Extraordinary Items
Net Income	60.9	114	156	-103	52.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	60.9	114	156	-103	52.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.187	0.242	0.062	-0.062	0.004
Dividends per Share